Durvalumab plus bevacizumab improves progression-free survival in liver cancer

In a phase 3 study involving 616 patients with unresectable hepatocellular carcinoma, the combination of durvalumab and bevacizumab, alongside transarterial chemoembolisation (TACE), significantly improved median progression-free survival to 15 months compared to 8.2 months with placebo. The hazard ratio for progression-free survival was 0.77, indicating a notable benefit, while safety assessments revealed manageable adverse events. This combination therapy shows promise in establishing a new standard of care for patients eligible for TACE.